Sexual dysfunction in men on buprenorphine – naloxone-based substitution therapy

Mattoo, Surendra Kumar; Ghosh, Abhishek; Subodh, BN; Basu, Debasish; Satapathy, Ashirbad; Prasad, Sambhu; Sharma, Mohit

doi:10.4103/psychiatry.indianjpsychiatry_195_19

Cited by 13 publications

(8 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…24 The study by Mattoo et al reported an average dose of 4.5±1.7. 11 In our study, the average Bup/Nal dose in the treatment group was very close to the average of our clinic, which is approximately 10 mg.…”

Section: Discussionsupporting

confidence: 79%

“…36 In the study of Mattoo et al, authors did not find any significance of sexual dysfunction with any of the clinical variables and the sociodemographic data. 11 In our study, noncommunication subscale of GRISS was found to be associated with comorbid psychiatric illness and tobacco use disorder but not associated with medical comorbidities and condom use. Being single was found to be associated with higher infrequency scores among the GRISS subscales.…”

mentioning

confidence: 41%

“…According to a recent study with opioid use disorder patients, ED was the third most common sexual dysfunction (77.5%), after hypoactive sexual desire (92.5%) and intercourse dissatisfaction (95%) in patients treated with Bup/Nal combination treatment. 11 In meta-analysis comparing studies of methadone and buprenorphine-based treatments, hypoactive sexual desire was shown to be the most abundant symptom. 10 Another meta-analysis confirmed that prevalence of ED was more common (relative risk = 1.96; 95% CI:1.66–2.32) in chronic treatment congruent with the past research findings.…”

Section: Discussionmentioning

confidence: 99%

“…10 Despite the widely reported sexual adverse effects of methadone maintenance treatment (MMT), data concerning Bup/Nal treatment is limited and controversial. 11 The results of the studies comparing the sexual adverse effects of buprenorphine maintenance treatment (BMT) and MMT were found to be controversial as well. 10 Considering the limitations in some of these studies (eg, small sample sizes, lack of control group) there is a need to perceive more on the subject.…”

Section: Introductionmentioning

confidence: 99%

“… 10 Despite the widely reported sexual adverse effects of methadone maintenance treatment (MMT), data concerning Bup/Nal treatment is limited and controversial. 11 …”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

<p>Sexual Adverse Effects and Erectile Dysfunction During Buprenorphine/Naloxone Combination Treatment for Opioid Use Disorders</p>

Beştepe

Tunali

Sarıdoğan

2020

NDT

View full text Add to dashboard Cite

Background and Objectives Compliance and maintenance of abstinence is a major issue in substance use disorders. Adverse effects of opioid maintenance treatments (OMT) include sexual dysfunctions. There is a vast amount of studies regarding sexual adverse effects of conventional OMTs; however, information regarding buprenorphine/naloxone (Bup/Nal) combination is limited, mostly evaluated in western populations and controversial. In this study, we aimed to assess the sexual adversities of Bup/Nal treatment in a Turkish alcohol and substance use disorder treatment center sample. Materials and Methods We recruited 100 subjects continuing sublingual Bup/Nal combination and 35 control subjects. Subjects were evaluated via the the Golombok-Rust Inventory of Sexual Satisfaction (GRISS) for sexual dysfunction and for erectile dysfunction (ED) with the International Index of Erectile Function-5 (IIEF-5) as a comparison. Results The mean dose of our treatment was 9.05. Overall sexual dysfunction scores were not significantly different in between groups with GRISS. ED and noncommunication scores were significantly higher in the Bup/Nal treatment group than the control group (p = 0.002, p = 0.02, respectively). Along with the increased ED scores in GRISS, IIEF-5 total scores also revealed more significant severity of the ED in the Bup/Nal group (p = 0.001). Conclusion Buprenorphine/naloxone combination lead to a higher degree of ED severity than the non-treatment controls. Noncommunication seems to play a role as a risk factor for ED in patients with opioid use disorder. Thus, effective communication can be a key factor for sexual assertivity and disclosing the sexual adverse effects to the clinicians as well as staying in the treatment.

show abstract

Section: Discussionsupporting

confidence: 79%

mentioning

confidence: 41%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“… 10 Despite the widely reported sexual adverse effects of methadone maintenance treatment (MMT), data concerning Bup/Nal treatment is limited and controversial. 11 …”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

<p>Sexual Adverse Effects and Erectile Dysfunction During Buprenorphine/Naloxone Combination Treatment for Opioid Use Disorders</p>

Beştepe

Tunali

Sarıdoğan

2020

NDT

View full text Add to dashboard Cite

show abstract

Comparative evaluation of craving, sleep quality, sexual function and quality of life in opioid use disorder patients in remission with buprenorphine/naloxone maintenance treatment

Türker,

Erdoğan,

Cinemre

et al. 2024

Human Psychopharmacology

View full text Add to dashboard Cite

AimTo compare opioid use disorder (OUD) patients who continue to use opioids and are in remission with buprenorphine‐naloxone (B/N) in terms of some parameters and to evaluate the relationship between B/N dose and these parameters.MethodWe included 141 OUD patients in remission with B/N maintenance treatment for at least 6 months, 141 who still used opioids, and 141 healthy volunteers. Substance Craving Scale (SCS), Pittsburgh Sleep Quality Index (PSQI), Arizona Sexual Experiences Scale (ASEX), and Short Form 36 (SF‐36) were administered.ResultsPSQI scores and ASEX scores were higher in those who continued to use opiates than in OUD in remission, and in OUD in remission compared to controls. OUD patients with current opioid use also had lower SF‐36 scores compared to both patients in remission and healthy controls. SCS, PSQI, ASEX, and SF‐36 scores were similar when the three groups were examined based on the dosage of B/N (below 8, 8–15, and 16 mg/day and above) use in OUD in remission.ConclusionsQuality of life, craving, sleep and sexual functions improved significantly with B/N; however, these effects are not dependent on B/N dosage.

show abstract

Sexual Dysfunction in Persons Receiving Opioid Substitution Therapy

Choi

El‐Khatib

et al. 2020

Curr Sex Health Rep

View full text Add to dashboard Cite

Sexual dysfunction in men on buprenorphine – naloxone-based substitution therapy

Cited by 13 publications

References 25 publications

<p>Sexual Adverse Effects and Erectile Dysfunction During Buprenorphine/Naloxone Combination Treatment for Opioid Use Disorders</p>

<p>Sexual Adverse Effects and Erectile Dysfunction During Buprenorphine/Naloxone Combination Treatment for Opioid Use Disorders</p>

Comparative evaluation of craving, sleep quality, sexual function and quality of life in opioid use disorder patients in remission with buprenorphine/naloxone maintenance treatment

Sexual Dysfunction in Persons Receiving Opioid Substitution Therapy

Contact Info

Product

Resources

About